We envision a world where every patient has an affordable solution.

The goal of Ion Biotechnology México S.A. de C.V. is to commercialize IBAL in several Latino markets.

Initially developing in Mexico to then further expanding into additional Central and South American territories using prior clinical data in submission to the regulatory authorities of those regions.

Its strategy is to develop a pipeline of API drug candidates, consisting of combinations of metal ions, indications, and administration methods.

It will collaborate with its licensed partners to conduct clinical trials, and then sublicense to multiple bio/pharma companies within its territories.

Leading the work to fully develop Ion Biotechnology's potential.